These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15754531)

  • 1. [Sonographic first trimester screening in Switzerland].
    Lapaire O; Sartorius G; Holzgreve W; Tercanli S
    Praxis (Bern 1994); 2005 Feb; 94(6):199-204. PubMed ID: 15754531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pregnancy outcome in 1,252 fetuses after nuchal translucency measurement in the 1st trimester].
    Horner E; Holzgreve W; Batucan C; Tercanli S
    Praxis (Bern 1994); 2002 Feb; 91(7):261-5. PubMed ID: 11883361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-trimester sonographic screening for Down syndrome.
    Malone FD; D'Alton ME;
    Obstet Gynecol; 2003 Nov; 102(5 Pt 1):1066-79. PubMed ID: 14672489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Investigation of ultrasound markers in screening fetal trisomy 21].
    Shi XM; Fang Q; Chen BJ; Xie HN; Xie YJ; Chen JH; Wu JZ
    Zhonghua Fu Chan Ke Za Zhi; 2013 Feb; 48(2):81-5. PubMed ID: 23544486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasonographic markers for chromosomal abnormalities in women with negative nuchal translucency and second trimester maternal serum biochemistry.
    Verdin SM; Whitlow BJ; Lazanakis M; Kadir RA; Chatzipapas I; Economides DL
    Ultrasound Obstet Gynecol; 2000 Oct; 16(5):402-6. PubMed ID: 11169322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Screening for aneuploidy by first trimester nuchal translucency measurement: results from a prospective trial including 1980 cases in a single center in Switzerland].
    Tercanli S; Holzgreve W; Batukan C; Gerber A; Ermis H; Miny P
    Ultraschall Med; 2002 Feb; 23(1):22-6. PubMed ID: 11842368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome.
    Kadir RA; Economides DL
    Ultrasound Obstet Gynecol; 1997 Apr; 9(4):244-7. PubMed ID: 9168574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interest of foetal nasal bone measurement at first trimester trisomy 21 screening.
    Weingertner AS; Kohler M; Firtion C; Vayssière C; Favre R
    Fetal Diagn Ther; 2006; 21(5):433-8. PubMed ID: 16912493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers.
    Muller F; Benattar C; Audibert F; Roussel N; Dreux S; Cuckle H
    Prenat Diagn; 2003 Oct; 23(10):833-6. PubMed ID: 14558029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population.
    Schuchter K; Hafner E; Stangl G; Ogris E; Philipp K
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
    Thilaganathan B; Slack A; Wathen NC
    Ultrasound Obstet Gynecol; 1997 Oct; 10(4):261-4. PubMed ID: 9383877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuchal translucency and first trimester biochemical markers for down syndrome screening: a cost-effectiveness analysis.
    Caughey AB; Kuppermann M; Norton ME; Washington AE
    Am J Obstet Gynecol; 2002 Nov; 187(5):1239-45. PubMed ID: 12439512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nuchal translucency: technical measurement and value].
    Broussin B; Sarramon MF
    J Radiol; 2002 Dec; 83(12 Pt 2):1891-8. PubMed ID: 12592151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester screening: an overview.
    Eiben B; Glaubitz R
    J Histochem Cytochem; 2005 Mar; 53(3):281-3. PubMed ID: 15750002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down syndrome screening in the first and second trimesters: what do the data show?
    Rosen T; D'Alton ME
    Semin Perinatol; 2005 Dec; 29(6):367-75. PubMed ID: 16533649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for Down's syndrome by fetal nuchal translucency measurement in a high-risk population.
    Pajkrt E; Mol BW; van Lith JM; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):156-62. PubMed ID: 9793186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
    Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nuchal translucency measurement--non invasive ultrasound screening for fetal abnormalities. Part II].
    Sieroszewski P; Baś-Budecka E
    Ginekol Pol; 2004 Mar; 75(3):192-6. PubMed ID: 15181876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Enlarged nuchal translucency with normal karyotype].
    Oueslati A; Amroussi A; Youssef A; Ben Ghezala M; Agrebi W; Ben Mefteh M; Oueslati H
    Tunis Med; 2008 Jun; 86(6):617-8. PubMed ID: 19216466
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.